Board of Directors
Kathryn G. Schubert, MPP, CAE
Kathryn (Katie) Schubert joined the Society for Women’s Health Research (SWHR) as President and CEO in April 2020. Under Katie’s leadership SWHR developed a strategic plan focused on fulfilling the organization’s mission of promoting research on biological sex differences in disease and improving women’s health through science, policy, and education. She previously worked for the Society for Maternal-Fetal Medicine (SMFM), where she served as the organization’s chief advocacy officer, growing SMFM’s role nationally and building its reputation in women’s health.
Katie is a trusted leader and consensus builder among women’s health stakeholders, particularly in the policy arena. She has served in multiple Board roles for nonprofit organizations in the Washington, DC-area, including as Chair of the Board of the Maternal Mental Health Leadership Alliance and as advisor to the John E. Lewy Fund for Children’s Health. She is a past president of Women in Government Relations.
Prior to SMFM, Katie served as senior vice president at CRD Associates, where she advised clients — including nonprofit patient advocacy groups, medical professional organizations, and private companies — on government relations and public policy related to health and biomedical research issues, among others. She has also spent time working in key legislative roles on Capitol Hill. She received her BA from Mary Washington College and her Masters of Public Policy from George Washington University. Katie lives in Virginia with her husband, three children, and dog George.
Phone: (202) 496-5004
Gretta Stone is a health policy communications consultant at Reservoir Communications Group with deep knowledge of the biopharmaceutical sector and the health system more broadly.
At Reservoir, she works with a range of clients on advocacy, reputation, and organization brand. Before coming to Reservoir, she served as Deputy Vice President of Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA), where she led a range of issues related to the value of medicines, the R&D process, FDA regulation, and personalized medicine. In her more than 15 years at PhRMA, she worked extensively on orphan drugs, cancer, the biopharmaceutical pipeline, the research ecosystem, the cost of medicines, and marketing and promotion. Prior to joining PhRMA, Stone worked in a lab researching language and the brain at Georgetown University, where she received a Bachelor of Science in biology.
Jenelle Krishnamoorthy, PhD
Jenelle S. Krishnamoorthy, PhD, is the associate vice president for global policy, communications and population health at Merck.
Prior to joining Merck in January 2015, Krishnamoorthy worked on health policy for 10 years for Sen. Tom Harkin (D-Iowa). She served for five years as the health policy director for the Senate’s Health, Education, Labor and Pensions Committee when Harkin was chairman. Krishnamoorthy first joined Harkin’s team as an American Association for the Advancement of Science (AAAS) Fellow in 2003 and 2004. During 2004 and 2005, she worked at the U.S. State Department in the Bureau of South Asian Affairs on health, science, technology, and environment issues with India on a AAAS Diplomacy Fellowship.
Trained as a licensed clinical psychologist, Krishnamoorthy completed her pediatric clinical psychology internship and postdoctoral fellowship at Brown Medical School, where she conducted research in the areas of childhood obesity and tobacco issues. She received her bachelor’s degree from Randolph-Macon College, her master’s degree from the University of Tennessee, and her doctorate from Virginia Commonwealth University.
Shontelle Dodson, PharmD
Shontelle Dodson, PharmD, is the Senior Vice President and Head of US Medical Specialties Business Unit at Astellas and has extensive clinical and research experience in the health care and pharmaceutical industries. She previously served as Senior Vice President and Head of Medical Affairs Americas at Astellas.
After several years of service in direct patient care at the Department of Veterans Affairs, Dodson spent 11 years at Pfizer Inc. in various leadership roles, including the U.S. Viagra Medical Team Leader and Senior Director, Group Leader supporting the urology and respiratory franchise. Following her work with Pfizer, Dodson served as Vice President of Medical Affairs at GTx Inc. In this capacity, she led the Phase 3 clinical development of a selective androgen receptor modulator for the prevention and treatment of muscle wasting in patients with cancer, including key economic and health outcomes assessments to support product utilization and valuation. Under her leadership at Astellas, the health outcomes group has pioneered multiple, innovative real world data projects, including two national registries in prostate cancer and overactive bladder, as well as partnered research with leading managed care and academic organizations.
She has received multiple awards for leadership and innovation during her career, including the National Healthcare Business Women’s Association Rising Star.
Dodson holds a Doctor of Pharmacy degree from Mercer University School of Pharmacy and completed a postdoctoral residency at the Department of Veterans Affairs Medical Center in Nashville, Tenn.
Patti Compton, MS
Patti Compton serves as the Head of Statistical Programming and Analysis at Pfizer.
With over 20 years pharmaceutical academic and industry experience, Ms. Compton has been responsible for leading efforts to build a sustainable framework to optimize data delivery including strengthening data reporting environments, quality indicators and data sharing capabilities. Currently, she is leading an implementation of a digitized analysis platform with modernized search, integration, and automation/ML to enable simplified workflows and predict risk. Additionally, she is accountable for developing functional sourcing strategies and partnerships and has implemented many development operational expansion efforts within Asia including China, India and Japan.
Ms. Compton also serves as the President of the Groton Pfizer Women’s Resource Group and works on several advisory committees with interests in sharing and expediting availability of data to patients, industry collaborators, and health authorities. She holds BA and MS degrees in Experimental Psychology from the University of Michigan and Eastern Michigan University.
Erika Miller, JD
Erika Miller, JD serves as Senior Vice President and Counsel at CRD Associates.
Through her career, she has developed broad experience in government relations representing a range non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations, including a number engaged on women’s health issues. Erika has expertise in the intricacies of Medicare policy and provides guidance to clients as they navigate the evolving area of health care payment and quality. Erika is a co-author of a chapter entitled, “Lobbying the Appropriations Process” in the American Bar Association Lobbying Manual.
A New Jersey native, Erika worked in the office of Congressman Steve Rothman of New Jersey where she handled immigration issues. Erika also worked in the U.S. Department of Health and Human Services Office on Women’s Health, where she monitored grant awards. Prior to joining CRD Associates in 2005, Erika worked at the lobbying firm of Broydrick & Associates representing health care interests. She served as co-chair of the Women in Government Relations Health & Social Polices Task Force and is member of the group Women Business Leaders in Health Care. Erika received her law degree from The American University, where she was an editor of the Administrative Law Review. She earned an undergraduate degree in Political Science from Colgate University.
Jim Carey is the CEO of JP Carey Consulting LLC, which provides comprehensive strategic consulting services on federal and state public policy and marketplace issues relevant to its clients.
Previously, Jim was Head of U.S. Policy and Government Affairs for Organon and Co., a global healthcare company, formed through a spinoff from Merck in June 2021, with a mission to deliver impactful medicines and solutions for a healthier every day. Organon’s vision is “A better and healthier every day for every woman.” In that role at Organon, Jim led federal and state policy and government relations and served on the leadership team for Organon’s External Affairs and ESG group.
Jim also serves as the Treasurer of The Biosimilars Forum, an organization founded to inform and support public policies that encourage awareness, access, and adoption of biosimilars in the United States. During his 7 years with Merck in U.S. Federal Policy in Washington, DC, Jim served as policy lead for Merck’s U.S. Biosimilars, Diabetes, Hepatitis, and HIV businesses. Prior to joining Merck in 2014, Jim was Vice President and Head of U.S. Corporate Policy for Novartis Corporation, also based in Washington, DC. His responsibilities included directing the Public Policy agenda for the Novartis Group Companies in the U.S., ensuring coordination and collaboration across all U.S. business units.
Jim has more than three decades of experience in pharmaceutical industry federal and state public policy. A native of Scranton, PA, Jim and his wife Cathy live in Alexandria, VA and have three adult children, Alison, Jackie, and Chris.
Anne B. Cropp, PharmD
Anne Cropp, PharmD, is Chief Scientific Officer of Early Access Care LLC, a health care company focused on facilitating all stakeholders involved in the review and approval of Expanded Access and Compassionate Use requests for investigational drugs.
Prior to founding Early Access Care, Cropp was Vice President in the Global Product Development Group at Pfizer Inc. She has 25 years of experience in the biopharmaceutical industry, marked by achievements in innovation and successful development of new drug products. As an innovator, Cropp has held a number of global leadership positions in R&D and has led matrixed development teams from Phase 1 through NDA/MAA submission and successful registration and commercialization. Her expertise in drug development spans Phases 1-4, both large and small molecules. She has expertise in planning and executing drug development programs for compounds with multiple routes of administration, including oral, intravenous, subcutaneous and inhalation, as well as devices for inhalation and injection.
Cropp has been responsible for the strategic planning, development and execution of investigational drugs across a wide spectrum of disease areas in adult and pediatric patients. She has developed and executed very large and mid-sized programs in disease areas that span Alzheimer’s disease, heart failure, hypercholesterolemia, hypertension, type I and II diabetes mellitus and vascular surgery.
Cropp served as Chair of the Pfizer Pediatric Council for eight years, and she advised pan-therapeutic area teams on issues related to planning for regulatory meetings, pediatric protocols, and execution of pediatric clinical trials.
Linda G. Griffith, PhD
Linda G. Griffith, PHD, is Professor of Teaching Innovation, Biological Engineering, and Mechanical Engineering, and Director of the Center for Gynepathology Research at the Massachusetts Institute of Technology (MIT).
Griffith received a bachelor’s degree from Georgia Tech and a PhD degree from the University of California at Berkeley, both in chemical engineering. She is a member of the National Academy of Engineering and the recipient of a MacArthur Foundation Fellowship.
Her research encompasses molecular-to-systems level analysis, design and synthesis of biomaterials, scaffolds, devices and micro-organs for a range of applications in regenerative medicine, tissue engineering, and in vitro drug development. A central theme is connecting the experimental systems to systems biology measurements. Most projects are highly interdisciplinary and translational, involving basic scientists, clinicians, and engineers, often with industry partners, to solve important problems in medicine and biology.
The Griffith lab also leads a substantial program to build the “Human Physiome on a Chip,” funded by DARPA and NIH. In this program, 10 microphysiological systems, including liver, gut, lung, and reproductive systems, are interconnected in a physiologically relevant manner. Griffith is also a member of SWHR’s Estrogen-Driven Diseases Network as both an endometriosis patient and a researcher whose work in endometriosis has been recognized by NIH’s Office of Research on Women’s Health as well as the Endometriosis Foundation of America.
Florence P. Haseltine, PhD, MD
Florence P. Haseltine, PhD, MD, is a board certified obstetrician and gynecologist and an expert in reproductive endocrinology. She is the founder of the Society for Women’s Health Research.
Haseltine received her undergraduate training at University of California at Berkeley, a doctorate in biophysics from the Massachusetts Institute of Technology, and an MD from the Albert Einstein College of Medicine. Following her internship at the University of Pennsylvania at Philadelphia and her residency at Boston Hospital for Women (Brigham and Women’s Hospital), she served as Assistant and Associate Professor in the Department of Ob/Gyn and Pediatrics at Yale University.
While at Yale University School of Medicine, she took a year of training at the School of Organization and Management in order to develop a proficiency in administration, policy, strategic planning and business development. She wrote computer programs for automating sperm counting and sold them to industry. She has served on the Scientific Advisory Board of Health Care Ventures, a venture capital group specializing in biotechnology.
The health of women and their advancement professionally are central issues for Haseltine. In 1990, she founded the Society for Women’s Health Research and was its first president. SWHR has brought the issue of research on women’s health to the attention of federal officials and prominent members of the media as well as placing it on the nation’s priority research agenda. As SWHR’s founder, Haseltine wrote mission statements, raised monies, established bylaws, and hired the original staff. She is also the founder of Haseltine Systems, a company devoted to easing travel for persons with disabilities.
Haseltine has co-edited and reviewed numerous publications and books on a range of topics, including reproductive biology, women’s health, and proceedings of NIH-sponsored conferences related to the reproductive sciences and population issues. She was also the founding editor of the Journal of Women’s Health. In addition, she has made many scientific, public, and media presentations across the country and internationally. She now concentrates on helping nonprofits in the medical advocacy area with their IT requirements. Her current activities include developing mobile apps for medicine. As an early adopter, her work as expanded to include such wearable devices as Google GLASS.
Haseltine was on the Board of Directors of the American Association for the Advancement of Science and the Society for Gynecologic Investigation. She is currently a board member of the American Women in Science and the Older Women’s League. She has been recognized for her contributions in the field of women’s health and reproductive science by election to the Institute of Medicine (IOM) (now the the National Academy of Medicine (NAM)) and by receiving a variety of accolades. These awards include the following: the Weizmann Honored Scientist Award, the American Woman’s Medical Association Scientist Award, the Advocacy Award from Research!America for the Society for Women’s Health Research, and Kilby Laureate. She was also an honoree for Health Hero of the American Health for Women Magazine and for Prevention Magazine “Hall of Fame;” and Ladies’ Home Journal “Champions of Women’s Health.” She has received lifetime achievement awards from the United Nations Population Fund (UNFPA) and from the Foundation for the History of Women in Medicine (FHWIM).
Judette Louis, MPH, MD
Dr. Louis is the Chair of the Department of OB/GYN at University of South Florida. She has a joint faculty appointment in both the College of Public Health and the College of Medicine.
A specialist in Maternal Fetal Medicine, Dr. Louis has been active in SMFM for many years. In addition to being a Past President, she has served on the group’s board of directors, as representative for the Women’s Preventive Services Initiative Taskforce, on its publications committee. She also earned SMFM’s President’s Award for Research Excellence. Her research in obstructive sleep apnea in pregnant women led to a career focused on maternal morbidity and mortality.
Dr. Louis has authored numerous scientific articles and book chapters on sleep apnea and maternal morbidity/mortality. She also served as a member of SWHR’s Interdisciplinary Network on Sleep, which worked to bring attention to sleep health issues in women and enhance discussions between health care providers and patients to better address women’s sleep needs. Through her work as a clinical leader for the Florida Perinatal Quality Collaborative, Dr. Louis has led statewide programs to improve management of obstetric emergencies in the state of Florida. She is passionate about making pregnancy safer for all women and in particular, improving maternal health across the lifespan.
Marianne Slight is the Director of Product Management at Verily, an Alphabet company combining a data-driven, people-first approach in precision health.
Marianne Slight leads evidence generation products at Verily, Alphabet’s healthcare and life sciences company that is focused on bringing the promise of precision health to everyone, every day.
Prior to Verily, she led products for healthcare analytics at Google Cloud, healthcare AI at Nuance, clinical quality and population health at Optum, and perioperative and critical care at Picis. She spent 10 years at Oracle, initially as a technical consultant and then leading multidimensional analytic solutions.
Understanding that healthcare data is naturally messy, siloed, and complex, she has concentrated on bringing scalable technologies for data and analytics from other industries into healthcare and life sciences. Her goal is to enable the richness of information to be unlocked from the raw data, so it becomes useful for both research and care, while safeguarding the consent of the patient. She holds a Physics degree from the University of Glasgow, and is a member of the Institute of Chartered Accountants of Scotland.
Michael Ybarra, MD
Michael Ybarra, MD, FACEP, FAPCR, is Vice President and Chief Medical Officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). As an organization, PhRMA advocates for public policies that support the innovative biopharmaceutical ecosystem. Dr. Ybarra manages teams responsible for coalition building, stakeholder engagement, and strategic partnerships domestically and internationally in support of PhRMA’s public policy priorities. That includes areas such as pandemic preparedness, industry’s COVID-19 response, and addressing the threat of antimicrobial resistance. In addition, his team advocates on issues related to implementation of the Inflation Reduction Act, Medicare Parts B, D, the 340B drug discount program, and the Food and Drug Administration. He engages with organizations across the health care ecosystem, including patient advocacy, civil rights, and multicultural organizations, as well as medical societies.
Dr. Ybarra is an emergency physician and a graduate of Stanford University and Georgetown University School of Medicine, where he also completed his residency training. He is an Assistant Professor of Emergency Medicine at Georgetown University School of Medicine where he continues to see patients in the emergency department while mentoring medical students, residents, and health policy fellows. For nearly a decade, he was an active leader in the American Academy of Emergency Medicine (AAEM), serving on the Board of Directors, Director of the Young Physicians Section, and President of the Resident and Student Association. He currently sits on the board of the Society for Women’s Health Research (SWHR) and the Academy of Physicians in Clinical Research (APCR). He is the alternate delegate for the APCR in the American Medical Association House of Delegates. He is also the author of several peer review publications and book chapters.